Clinical Trial Update: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating in situ immunomodulation using CDX-301, CDX-1140, and Poly-ICLC with radiation therapy in patients with unresectable and metastatic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Bone Sarcoma
• Breast Cancer
• Cutaneous Squamous Cell Carcinoma
• Melanoma
• Merkel Cell Carcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• CDX-1140
• CDX-301
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: University of Southern California | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING